Speaker

AFFILIATION:

Translational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.

POSITION TITLE:

Associate Research Fellow

EDUCATION/TRAINING:

2017/11-present, Associate Research Fellow, Translational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.

2015/01-2017/10, Post-doctoral Fellow, Department of Education and Research, Taichung Veterans General Hospital, Taichung, Taiwan.

2007/08-2015/01, M.S./Ph. D. program, Institute of Biomedical Science, National Chung-Hsing University, Taichung, Taiwan.

2005/08-2007/07, B.S., Department of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung, Taiwan.

HONORS:

*Allogeneic Bispecific Nanobody-CAR.BiTE-γδT Cell Therapy. Taiwan Innotech Expo (TIE) Award (2023).

*Artificial intelligence for identifying biomarkers and new drug development. National Innovation Award&Future Tech Award (2023).

*工程改質標靶外泌體搭載雙功能藥物應用於精準癌症治療. National Innovation Award&Future Tech Award (2022).

*Chimeric antigen receptor immune cell therapy for treating multiple types of solid tumors. National Innovation Award&Future Tech Award (2019).

RESEARCH INTERESTS:

Huang obtained a PhD degree in biomedical sciences from the National Chung-Hsing University in Taiwan. During his PhD he studied the mechanism and application of a synthetic TLR7 ligand imiquimod in skin cancers and psoriasis. He then went to China Medical University Hospital for a Assistant Research Fellow where he focused on the development of engineered immune cell and extracellular vesicle therapies, and translated to product development and further clinical trials

1. Engineered immune cell therapy

2. Engineered extracellular vesicles

3. Tumor immunology

PUBLICATIONS:

1. Zheng-Yi Li, Shu-Hao Chang, Kuang-Ting Liu, Alaina Edelie Wu, Chien-Sheng Hsu, Shi-Wei Huang, et al. Low-dose imiquimod induces melanogenesis in melanoma cells through an ROS-mediated pathway. J Dermatol Sci. 2024 Jan;113(1):18-25.

2. Shi-Wei Huang, Chih-Ming Pan, Yu-Chuan Lin, Mei-Chih Chen, et al. BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors. Adv Sci (Weinh). 2023 Jun;10(17):e2206856.

3. Yu-Chuan Lin, Chun-Hung Hua, Hsin-Man Lu, Shi-Wei Huang, et al. CAR-T cells targeting HLA-G as potent therapeutic strategy for EGFR-mutated and overexpressed oral cancer. iScience. 2023 Jan 31;26(3):106089.

4.Mei-Chih Chen, Meng-Yu Hung, Chih-Ming Pan, Shi-Wei Huang, et al. Pemetrexed combined with dual immune checkpoint blockade enhances cytotoxic T lymphocytes against lung cancer. Cancer Sci. 2023 Jul;114(7):2761-2773.

5.Shu-Hao Chang, Pei-Ying Lin, Tsai-Kun Wu, Chien-Sheng Hsu, Shi-Wei Huang, et al. Imiquimod-induced ROS production causes lysosomal membrane permeabilization and activates caspase-8-mediated apoptosis in skin cancer cells. J Dermatol Sci. 2022 Sep;107(3):142-150.

6.Chia-Ing Jan#, Shi-Wei Huang#, Peter Canoll, Jeffrey N Bruce, et al. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors. J Immunother Cancer. 2021 Oct;9(10):e003050.

7.Shu-Hao Chang, Chun-Ying Wu, Kai-Cheng Chuang, Shi-Wei Huang, et al. Imiquimod Accelerated Antitumor Response by Targeting Lysosome Adaptation in Skin Cancer Cells. J Invest Dermatol. 2021 Sep;141(9):2219-2228.e8.

8.Sin-Ting Wang, Shi-Wei Huang, Kuang-Ting Liu, Teng-Yu Lee, et al. Atorvastatin-induced senescence of hepatocellular carcinoma is mediated by downregulation of hTERT through the suppression of the IL-6/STAT3 pathway. Cell Death Discov. 2020 Mar 30:6:17.

9. Shi-Wei Huang, Sin-Ting Wang, Shu-Hao Chang, Kai-Cheng Chuang, et al. Imiquimod Exerts Antitumor Effects by Inducing Immunogenic Cell Death and Is Enhanced by the Glycolytic Inhibitor 2-Deoxyglucose. J Invest Dermatol. 2020 Sep;140(9):1771-1783.e6.

10.Kai-Cheng Chuang, Chuang-Rung Chang, Shu-Hao Chang, Shi-Wei Huang, et al. Imiquimod-induced ROS production disrupts the balance of mitochondrial dynamics and increases mitophagy in skin cancer cells. J Dermatol Sci. 2020 Jun;98(3):152-162.

11.Jiaan-Der Wang, Ya-Yu Wang, Shih-Yi Lin, Cheng-Yi Chang, Jian-Ri Li, Shi-Wei Huang, et al. Exosomal HMGB1 Promoted Cancer Malignancy. Cancers (Basel). 2021 Feb 19;13(4):877.

12.Jun-Kai Kao, Shih-Chung Wang, Li-Wei Ho, Shi-Wei Huang, et al. M2-like polarization of THP-1 monocyte-derived macrophages under chronic iron overload. Ann Hematol. 2020 Mar;99(3):431-441.

13.Shu-Chung Hsieh, Chih-Sheng Lai, Chi-Hao Chang, Jung-Hsing Yen, Shi-Wei Huang, et al. Nitric oxide: Is it the culprit for the continued expansion of keloids? Eur J Pharmacol. 2019 Jul 5:854:282-288.